Emerging nanoformulations of Plectranthus-derived abietane diterpenoids for cancer treatment
Planta Medica · 01.03.2026 · 92 (03) · 419
DOI: 10.1055/s-0045-1815457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von G Bangay und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Nanoparticles (NPs) play a crucial role in enhancing drug delivery systems by boosting bioavailability and enabling targeted release, particularly when used in combination with natural compounds [ 1 ]. This synergy can lead to more efficient treatments with fewer adverse effects. When natural products are encapsulated within NPs, the resulting formulations often demonstrate improved drug loading, controlled release profiles, prolonged circulation time, and reduced toxicity. Among various nanoparticle platforms, metal-based NPs especially gold nanoparticles ( AuNPs ) are particularly attractive due to their straightforward synthesis, stability, and distinct physicochemical properties. These attributes make them well-suited for delivering both drugs and genes, especially in the context of cancer therapy. Abietane diterpenoids, such as 7α-acetoxy-6β-hydroxyroyleanone ( Roy ), derived from Plectranthus species, have shown cytotoxic activity. However, their clinical potential is hampered by poor aqueous solubility and limited bioavailability. To overcome these challenges, Roy and a related esterified compound were incorporated into AuNP-based nanocarriers [ 2 ]. These formulations were evaluated based on parameters such as particle size, polydispersity index (PDI), surface charge (zeta potential), and drug encapsulation efficiency. In vitro anticancer studies using breast cancer cell lines (MDA-MB-231, 4T1, and MCF7) indicated that Roy -loaded AuNPs exhibited significantly stronger cytotoxicity compared to either Roy alone or unmodified AuNPs. Furthermore, the Roy-AuNPs displayed selective activity against cancer cells while sparing normal human dermal fibroblasts (HDFs), suggesting their potential as targeted anticancer agents. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Bangay, G., Isca, V. S., Alarcón, J. F., Ntungwe, E., Morais, J., Viana, A. S., Reis, C. P., Pereira-Leite, C., Saraiva, L., Díaz-Lanza, A. M., Puigvert, C. F., & Rijo, P. (2026). Emerging nanoformulations of Plectranthus-derived abietane diterpenoids for cancer treatment. Planta Medica, 92(03), 419. https://doi.org/10.1055/s-0045-1815457
Vancouver
Bangay G, Isca VS, Alarcón JF, Ntungwe E, Morais J, Viana AS, et al. Emerging nanoformulations of Plectranthus-derived abietane diterpenoids for cancer treatment. Planta Medica. 2026;92(03):419. doi:10.1055/s-0045-1815457
BibTeX
@article{Bangay2026,
author = {Bangay, G and Isca, VM S and Alarcón, J Fernandez and Ntungwe, E and Morais, J and Viana, A S and Reis, C P and Pereira-Leite, C and Saraiva, L and Díaz-Lanza, A M and Puigvert, C F and Rijo, P},
title = {Emerging nanoformulations of Plectranthus-derived abietane diterpenoids for cancer treatment},
journal = {Planta Medica},
year = {2026},
volume = {92},
number = {03},
pages = {419},
doi = {10.1055/s-0045-1815457}
}
EUVIMED